DNTH
Dianthus Therapeutics, Inc.
$105.60
+10.25
(+10.75%)
Mkt Cap
4.41B
Volume
1,025,194
52W Range
18.08-105.72
Sector
Healthcare
Beta
0.09
EPS (TTM)
-0.11
P/E Ratio
-9.81
Revenue (TTM)
1.34M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (162.34M) | (84.97M) | (43.55M) | (28.48M) | (13.11M) | (74.94M) | (76.77M) | (57.52M) | (35.49M) | (9.43M) |
| EPS | -4.20 | -2.55 | -8.45 | -7.60 | -3.82 | -27.30 | -33.18 | -27.62 | -16.05 | -4.27 |
| Free Cash Flow | (129.27M) | (78.28M) | (36.97M) | (29.21M) | (60.80M) | (64.42M) | (60.16M) | (49.56M) | (24.46M) | (6.67M) |
| FCF / Share | -3.42 | -2.35 | -7.17 | -7.79 | -17.70 | -23.47 | -26.01 | -23.80 | -11.07 | -3.02 |
| Operating CF | (129.06M) | (78.18M) | (36.86M) | (29.07M) | (59.53M) | (64.02M) | (57.10M) | (41.89M) | (22.26M) | (6.53M) |
| Total Assets | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M | 161.62M | 161.51M | 157.31M | 54.46M | 11.34M |
| Total Debt | 1.39M | 1.49M | 585,000 | 788,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 51.09M | 22.79M | 132.32M | 15.37M | 131.65M | 58.15M | 65.07M | 58.34M | 51.57M | 4.54M |
| Book Value | 493.40M | 352.48M | 168.87M | 73.66M | 172.67M | 143.91M | 141.19M | 145.65M | 50.32M | 9.04M |
| Return on Equity | -0.33 | -0.24 | -0.26 | -0.39 | -0.08 | -0.52 | -0.54 | -0.39 | -0.71 | -1.04 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 463,000 | 284,000 | 396,000 | 193,000 | 1.16M | 1.33M | 2.17M | 1.86M | 874,000 | 457,000 | 924,000 | 969,000 |
| Net Income | (40.83M) | 97.91M | (36.77M) | (31.63M) | (29.51M) | (28.44M) | (25.17M) | (17.61M) | (13.75M) | (10.56M) | (14.76M) | (11.14M) |
| EPS | -0.85 | 2.59 | -0.97 | -0.88 | -0.82 | -0.81 | -0.74 | -0.51 | -0.54 | -2.33 | -3.78 | -0.87 |
| Free Cash Flow | (28.87M) | (47.12M) | (30.56M) | (23.94M) | (27.65M) | (27.48M) | (21.29M) | (14.54M) | (14.97M) | (11.86M) | 1.64M | (4.75M) |
| FCF / Share | -0.60 | -1.25 | -0.81 | -0.67 | -0.77 | -0.78 | -0.62 | -0.42 | -0.58 | -2.62 | 0.42 | -1.25 |
| Operating CF | (28.86M) | (46.98M) | (30.55M) | (23.89M) | (27.63M) | (27.44M) | (21.27M) | (14.53M) | (14.94M) | (11.85M) | 1.50M | (4.73M) |
| Total Assets | 1.25B | 530.92M | 577.45M | 326.08M | 348.58M | 374.01M | 354.25M | 368.96M | 382.46M | 179.41M | 192.46M | 78.64M |
| Total Debt | 1.36M | 1.39M | 1.28M | 1.33M | 1.40M | 1.49M | 311,000 | 407,000 | 497,000 | 585,000 | 670,000 | 0 |
| Cash & Equiv | 627.67M | 51.09M | 55.98M | 13.24M | 10.12M | 22.79M | 33.67M | 314.17M | 329.72M | 132.32M | 157.28M | 62.63M |
| Book Value | 1.20B | 493.40M | 546.45M | 303.08M | 328.61M | 352.48M | 337.90M | 358.22M | 372.69M | 168.87M | 178.38M | 74.60M |
| Return on Equity | -0.03 | 0.20 | -0.07 | -0.10 | -0.09 | -0.08 | -0.07 | -0.05 | -0.04 | -0.06 | -0.08 | -0.15 |
DNTH News
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics to Participate in Two Investor Conferences
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish